Empreses emergents
2022
SUCCIPRO SLEXPLOTAR L'EIX SUCCINATO-METABÒLIC-INFLAMATORIA PER CREAR TERAPEUTICS NOVES DE PRIMER CLASS PER A MALALTIES INFLAMATORIES I METABÒLICES Eines propietàries úniques per generar un pipeline de candidats preclínics centrats en malalties inflamatòries i metabòliques.
Adreça
Carrer Doctor Mallafré Guasch 4, 43005 Tarragona, Espanya
Propietat CERCA
Reus, Spain
2005
Institut de Recerca Biomèdica Catalunya Sud (IRB CatSud)
Altres accionistes públics catalans
Logotip
Àrees d'estat i deeptech
Estat de l'empresa i àrees de tecnologia profunda de l'empresaEstat de l'empresa
Àrea DeepTech
Informació sobre la spin-off
Descripció de l'empresa
OUR MISSION
Carry out the preclinical and early clinical development of succinate-modulating therapies for inflammatory and metabolic diseases, particularly obesity, type 2 diabetes and Crohn’s disease.
OUR VISION
Contribute to the long-term health of the people through science and provide effective solutions to people suffering from illnesses with a strong chronic inflammatory component by lowering succinate levels.
OUR STORY
SUCCIPRO is a project born from solid science on succinate pathophysiology from the DIAMET Research group (www.diamet.org), located at IISPV (www.IISPV.cat). SUCCIPRO is exclussively focused on succinate-modulating therapies.
Carry out the preclinical and early clinical development of succinate-modulating therapies for inflammatory and metabolic diseases, particularly obesity, type 2 diabetes and Crohn’s disease.
OUR VISION
Contribute to the long-term health of the people through science and provide effective solutions to people suffering from illnesses with a strong chronic inflammatory component by lowering succinate levels.
OUR STORY
SUCCIPRO is a project born from solid science on succinate pathophysiology from the DIAMET Research group (www.diamet.org), located at IISPV (www.IISPV.cat). SUCCIPRO is exclussively focused on succinate-modulating therapies.
Descripció del producte
Since succinate is elevated in many pathological situations with a metabolic and/or a inflammatory component, we are currently developing drugs able to reduce succinate to improve metabolism and reduce inflammation, being our first clinical indication type 2 diabetes.
We are developing first-in-class, gut- restricted, monitorable, succinate-modulating therapies as a new opportunity for patients with metabolic and inflammatory diseases.
Specific succinate consuming bacteria is associated to high levels of circulating succinateWe have demonstrated that intestinal succinate is a relevant source of circulating succinate, thus setting the stage for the development of our propietary gut-restricted succinate-decreasing therapies to treat inflammatory and metabolic diseases, being type 2 diabetes our first clinical indication.
Fields related:
Hypertension
Cancer
Type 2 Diabetes
Crohn's Disease
Ischemic Heart Disease
Obesity
Nonalcoholic Fatty Liver
We are developing first-in-class, gut- restricted, monitorable, succinate-modulating therapies as a new opportunity for patients with metabolic and inflammatory diseases.
Specific succinate consuming bacteria is associated to high levels of circulating succinateWe have demonstrated that intestinal succinate is a relevant source of circulating succinate, thus setting the stage for the development of our propietary gut-restricted succinate-decreasing therapies to treat inflammatory and metabolic diseases, being type 2 diabetes our first clinical indication.
Fields related:
Hypertension
Cancer
Type 2 Diabetes
Crohn's Disease
Ischemic Heart Disease
Obesity
Nonalcoholic Fatty Liver